The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Bacterial vaginosis: An insight into the prevalence, alternative treatments regimen and it's associated resistance patterns
Abstract
Bacterial Vaginosis (BV) is a complex polymicrobial infection of vagina that shifts the paradigms of vaginal flora from lactobacilli to opportunistic pathogens. BV is catagorized by greyish white discharge, pH greater than 4.5. It results in the preterm labor, abortion, pelvic inflammatory disorders, post cesarean infections. BV is associated with Sexually Transmitted Diseases (STDs) or immune deficiency disorders like Human Immunodeficiency Virus, Human Papilloma Virus, Herpes Simplex Virus 1 and 2, and Neisseria gonorrhoeae. The prevalence rate is about 21.2 million (29.2%) worldwide. BV is more frequent in black females as compared to white females, independent of geographical distribution. Globally, BV is treated with the current recommended antibiotic therapy including Metronidazole and Clindamycin. The recurrence rates are 76% and occur within 06 months of treatment due to antibiotic resistance against pathogenic bacteria and their biofilms. The antibiotic resistance is a global health issue which directs the attentions towards other treatments. One of these is the treatment of sex partners, thus helping to stop the recurrence rates in females. However, this method does not show any positive results. Probiotic therapy is an incorporation of Lactobacilli orally or intravaginally for the recolonization of healthy microbes. This therapy has exhibited promising results but some studies revealed that Probiotic therapy does not control the recurrence rate. The other methods are in trials period and none of them are used clinically or commercially available for the treatment. The thermoplastic polyurethane (TPU) intravaginal rings contain lactic acid and metronidazole showed promising results in trials of BV treatment. The vaginal acidifiers are used as an alternative method to maintain the vaginal pH but the process of douching is a major limitation. The activated charcoal is used to treat BV patients in clinical trials showed decrease in the pH with only 3.1% loss of lactobacilli. Phage therapy is a reemerging field to overcome the bacterial resistance. They are host specific and easier to handle. They can be used naturally, synthetically; phage cocktails and phage-antibiotics combination can be used. Phages show auspicious results for the treatment of bacterial infections as compared to antibiotics as they also treat biofilms. This is one of the promising therapy in future to treat infections with no side effects. Phage therapy can be used in pharmaceuticals according to Food and Drug Administration (FDA) guidelines. Taken together, it is suggested that large funding is required by pharmaceutical sector or government for further investigation of bacteriophages to be used against BV pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials
Bikard, D., Euler, C. W., Jiang, W., Nussenzweig, P. M., Goldberg, G. W., Duportet, X., Fischetti, V. A., & Marraffini, L. A. (2014) · Nature Biotechnology · doi:10.1038/nbt.3043 · Cited by 986
Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases
Citorik, R. J., Mimee, M., & Lu, T. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.3011 · Cited by 808
Koumans, E. H., Sternberg, M., Bruce, C., McQuillan, G., Kendrick, J., Sutton, M., & Markowitz, L. E. (2007) · Sexually Transmitted Diseases · doi:10.1097/olq.0b013e318074e565 · Cited by 761
Bacterial vaginosis and HIV acquisition: A meta-analysis of published studies
Atashili, J., Poole, C., Ndumbe, P. M., Adimora, A. A., & Smith, J. S. (2008) · AIDS · doi:10.1097/qad.0b013e3283021a37 · Cited by 706
Jordan, T. C., Burnett, S. H., Carson, S., Caruso, S. M., Clase, K., DeJong, R. J., Dennehy, J. J., Denver, D. R., Dunbar, D., Elgin, S. C. R., et al. (2014) · mBio · doi:10.1128/mbio.01051-13 · Cited by 509
The role of lactobacilli and probiotics in maintaining vaginal health
Borges, S., Silva, J., & Teixeira, P. (2014) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-013-3064-9 · Cited by 397
Gillet, E., Meys, J. F., Verstraelen, H., Bosire, C., De Sutter, P., Temmerman, M., & Broeck, D. V. (2011) · BMC Infectious Diseases · doi:10.1186/1471-2334-11-10 · Cited by 354
Anukam, K. C., Osazuwa, E., Osemene, G. I., Ehigiagbe, F., Bruce, A. W., & Reid, G. (2006) · Microbes and Infection · doi:10.1016/j.micinf.2006.08.008 · Cited by 276
Probiotics for the treatment of women with bacterial vaginosis
Falagas, M. E., Betsi, G. I., & Athanasiou, S. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01688.x · Cited by 253
Mastromarino, P., Macchia, S., Meggiorini, L., Trinchieri, V., Mosca, L., Perluigi, M., & Midulla, C. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02112.x · Cited by 194
Cited by
The Female Vaginal Microbiome in Health and Bacterial Vaginosis
Chen, X., Lu, Y., Chen, T., & Li, R. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.631972 · Cited by 451
Bacterial vaginosis: A state of microbial dysbiosis
Mondal, A. S., Sharma, R., & Trivedi, N. (2023) · Medicine in Microecology · doi:10.1016/j.medmic.2023.100082 · Cited by 44
He, Y., Na, R., Niu, X., Xiao, B., & Yang, H. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.568178 · Cited by 35
Zeng, X., An, R., & Li, H. (2023) · Open Medicine · doi:10.1515/med-2023-0743 · Cited by 10
Metadata
- Authors
- Javed, A., Parvaiz, F., & Manzoor, S.
- Venue
- Microbial Pathogenesis
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 127
- Pages
- 21-30
- ISSN
- 0882-4010 (ISSN-L)
- OpenAlex
- W2903509631
- Cited by
- 161
- References
- 14
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.